Exchange: NASDAQ·Updated 09:41 AM EDT
IKT logo

IKT Inhibikase Therapeutics Inc

$2.29
$0.01
(0.43%)
Today
EarningsNov 13
Mkt Cap$320.93M
Vol225.00

About IKT

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in development of protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. The company was founded by Milton H. Werner in September 2008 and is headquartered in Wilmington, DE.
47

Neutral Sentiment

How do you feel about IKT?

Advertisement|Remove ads.